Evidence map›Paper›PMID 31850282›Full record

ArticleOncolytic virotherapy2019

Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus.

Chase Burton, Mee Y Bartee, Eric Bartee

Open access · diamondAbstract read
In one paragraph

Article in Oncolytic virotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Chase BurtonDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Mee Y BarteeDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Eric BarteeDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Medical University of South Carolina · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Jian Ouyang · 2009 to 2026
$42.7M
Treatment of multiple myeloma using oncolytic myxoma virusR01CA194090 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BARTEE, ERIC CARTER · 2016 to 2020
$1.7M
Rationally combining oncolytic virotherapy and TIM3 blockadeR21AI142387 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BARTEE, ERIC CARTER · 2019 to 2020
$414k
Treatment of transplanted and established multiple myeloma using oncolytic myxomaK22AI095372 · NIAID · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BARTEE, ERIC CARTER · 2013 to 2014
$262k
NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA194090NIAID NIH HHS K22 AI095372NIAID NIH HHS R21 AI142387
6 · The paper itself

Abstract

introductionCancer has become one of the most critical health issues of modern times. To overcome the ineffectiveness of current treatment options, research is being done to explore new therapeutic modalities. One such novel treatment is oncolytic virotherapy (OV) which uses tumor tropic viruses to specifically target and kill malignant cells. While OV has shown significant promise in recent clinical trials, the therapeutic use of viruses poses a number of unique challenges. In particular, obtaining effective viral spread throughout the tumor microenvironment remains problematic. Previous work has suggested this can be overcome by forcing oncolytic viruses to induce syncytia formation.

methodsIn the current work, we generated a series of recombinant myxoma viruses expressing exogenous fusion proteins from other viral genomes and examined their therapeutic potential in vitro and in vivo.

resultsSimilar to previous studies, we observed that the expression of these fusion proteins during myxoma infection induced the formation of multinucleated syncytia which increased viral spread and lytic potential compared to non-fusogenic controls. Contrary to expectations, however, the treatment of established tumors with these viruses resulted in decreased therapeutic efficacy which corresponded with reduced viral persistence. DISCUSSION: These findings indicate that enhanced viral spread caused by syncytia formation can actually reduce the efficacy of OV and supports a number of previous works suggesting that the in vitro properties of viruses frequently fail to predict their in vivo efficacy.

Indexed as

fusogeniclung cancermyxoma virusoncolytic virotherapysyncytia

Identifiers

PMID31850282
PMCPMC6910101
OpenAlexW2993058851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.